Jessica A. Bisignano

Jessica A. Bisignano

Partner Corporate & Finance

Philadelphia

+1 267 675 4643

[email protected]

Jessica A. Bisignano

Overview
Experience
Credentials
Insights and events

Jessica A. Bisignano advises both public and private companies in a variety of transactions and on day-to-day corporate legal matters. She works closely with clients to get to know their businesses, understand their strategic goals, and help them anticipate and resolve issues that arise during the course of a transaction or representation.

Jessica focuses on U.S. and international business transactions, including mergers and acquisitions, capital markets transactions, and commercial transactions. She also advises on SEC disclosure, compliance, and corporate governance matters. Jessica has represented companies spanning a number of industries, particularly in the life sciences, pharmaceutical, consumer, technology, and financial services sectors.

Representative experience

Represented a leading developer and manufacturer of recombinant proteins in its auction and subsequent US$1.85bn sale to a global supplier of scientific instrumentation, reagents, and consumables.

Represents a developer of a 3D geolocation services in public company aspects of its SPAC merger and ongoing SEC reporting and Nasdaq compliance.

Represented a life sciences and health care contract manufacturing company in its auction and subsequent sale to a leading manufacturer of consumer goods.

Represented a clinical-stage biopharmaceutical company focused on respiratory diseases in its acquisition of a private drug development company focused on therapeutics for rare pulmonary diseases.

Represented a global leader of life science research and clinical diagnostic products in multiple acquisitions and investment transactions coupled with options to acquire.

Represented a multinational specialty pharmaceutical company in an option to acquire ophthalmology assets of a private ophthalmology company.

Represents a leading global life sciences company in its ongoing SEC reporting and NYSE compliance as well as on corporate governance issues.